Description

Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.-4°C (Powder, sealed storage, away from moisture)-Applications–Formula-C26H44NNaO6S-Citation–References-[1]Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5. |[2]Angelico M, et al. Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs. Scand J Gastroenterol. 1995 Dec;30(12):1178-85. |[3]Angelico M, et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. Dig Dis Sci. 1994 Nov;39(11):2389-97. |[4]Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5. |[5]Solmon Kusuma S, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2014, 14(9): 1237-1248. -CASNumber-38411-85-7-MolecularWeight-521.69-Compound Purity-98.0-SMILES-C[C@@]12[C@]3([H])[C@](C[C@@H]([C@]1([H])C[C@@H](CC2)O)O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@H](C)CCC(NCCS(=O)(O[Na])=O)=O)C-Research_Area-Inflammation/Immunology-Solubility-H2O : 62.5 mg/mL (ultrasonic)-Target-Interleukin Related;TNF Receptor-Isoform-IL-6;TNFRSF1A/CD120a-Pathway-Apoptosis;Immunology/Inflammation-MCE Product type-Biochemical Assay Reagents